Sandostatin and the Belfast experience.

Abstract

Twenty-four patients with 26 apudomas have been treated with Sandostatin (octreotide) in Belfast. The 2 patients with vipoma showed an excellent response clinically and biochemically. Of 15 patients with carcinoids, Sandostatin improved the diarrhoea in 70%, flush in 58%, and wheeze in 100% of patients. Patients with insulinoma and the Zollinger-Ellison syndrome were unresponsive to Sandostatin. In general, the response to Sandostatin appeared to decline as the tumour size increased and tumour markers rose. Side effects have not been a problem.

• Authors: K D Buchanan, J S Collins, A Varghese, C F Johnston, C Shaw
• Journal: Digestion (Digestion) Vol. 45 Suppl 1 Pg. 11-4; discussion 15-6 ( 1990) ISSN: 0012-2823 [Print] Switzerland
• PMID: 2159429 (Publication Type: Journal Article)

Chemical References

• Octreotide

Topics

• Apudoma (drug therapy)
• Carcinoid Tumor (drug therapy)
• Diarrhea (drug therapy)
• Female
• Flushing (drug therapy)
• Gastrinoma (drug therapy)
• Humans
• Insulinoma (drug therapy)
• Northern Ireland
• Octreotide (therapeutic use)
• Respiratory Sounds
• Vipoma (drug therapy)
• Zollinger-Ellison Syndrome (drug therapy)